[1] |
Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States[J]. JAMA Oncol, 2017, 3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.
pmid: 28448665
|
[2] |
Virarkar M, Vulasala SS, Morani AC, et al. Neuroendocrine Neoplasms of the Gynecologic Tract[J]. Cancers(Basel), 2022, 14(7):1835. doi: 10.3390/cancers14071835.
|
[3] |
Feng BJ, Li TH, Li YH, et al. Case series of ovarian neuroendocrine carcinoma: overview of clinicopathological features[J]. BMC Womens Health, 2023, 23(1):595. doi: 10.1186/s12905-023-02722-4.
|
[4] |
Soga J, Osaka M, Yakuwa Y. Carcinoids of the ovary: an analysis of 329 reported cases[J]. J Exp Clin Cancer Res, 2000, 19(3):271-280.
pmid: 11144518
|
[5] |
Georgescu TA, Bohiltea R, Munteanu O, et al. A mini-review regarding the carcinogenesis and morphology of serous tumors of the ovary, fallopian tube and peritoneum[J]. J Mind Med Sci, 2021, 8(1):44-52. doi: 10.22543/7674.81.P4452.
|
[6] |
Zhai LR, Zhang XW, Yu T, et al. Primary ovarian carcinoid: Two cases report and review of literature[J]. Medicine(Baltimore), 2020, 99(40):e21109. doi: 10.1097/MD.0000000000021109.
|
[7] |
Sharma R, Biswas B, Wahal SP, et al. Primary ovarian carcinoid in mature cystic teratoma: A rare entity[J]. Clin Cancer Investig, 2014, 4:80. doi: 10.4103/2278-0513.125803.
|
[8] |
Choi HY, Pak MG, Park JW. Fortuitously detected primary ovarian carcinoid tumor: A case report[J]. Medicine(Baltimore), 2023, 102(31):e34391. doi: 10.1097/MD.0000000000034391.
|
[9] |
Somak R, Shramana M, Vijay S, et al. Primary carcinoid tumor of the ovary: a case report[J]. Arch Gynecol Obstet, 2008, 277(1):79-82.
pmid: 17611764
|
[10] |
Georgescu TA, Bohiltea R, Varlas V, et al. A 15-year comprehensive literature review of 99 primary ovarian carcinoid tumors[J]. Clin Exp Obstet Gynecol, 2022,49:1. doi: 10.31083/j.ceog4901016.
|
[11] |
Wilkowske MA, Hartmann LC, Mullany CJ, et al. Progressive carcinoid heart disease after resection of primary ovarian carcinoid[J]. Cancer, 1994, 73(7):1889-1891. doi: 10.1002/1097-0142(19940401)73:7<1889::aid-cncr2820730719>3.0.co;2-3.
|
[12] |
Pang L, Guo Z. Primary neuroendocrine tumors of the ovary: Management and outcomes[J]. Cancer Med, 2021, 10(23):8558-8569. doi: 10.1002/cam4.4368.
|
[13] |
Park HK. Neuroendocrine Carcinomas of the Uterine Cervix, Endometrium, and Ovary Show Higher Tendencies for Bone, Brain, and Liver Organotrophic Metastases[J]. Curr Oncol, 2022, 29(10):7461-7469. doi: 10.3390/curroncol29100587.
pmid: 36290864
|
[14] |
Eichhorn JH, Young RH. Neuroendocrine tumors of the genital tract[J]. Am J Clin Pathol, 2001, 115(Suppl):S94-S112. doi: 10.1309/64CW-WKGK-49EF-BYD1.
|
[15] |
Howitt BE, Kelly P, McCluggage WG. Pathology of Neuroendocrine Tumours of the Female Genital Tract[J]. Curr Oncol Rep, 2017, 19(9):59. doi: 10.1007/s11912-017-0617-2.
pmid: 28735441
|
[16] |
Georgescu TA, Bohiltea RE, Munteanu O, et al. Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract[J]. Medicina(Kaunas), 2021, 57(12):1338. doi: 10.3390/medicina57121338.
|
[17] |
卢淮武, 叶栋栋, 吴斌, 等. 《2023 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2023, 39(1):58-67. doi: 10.19538/j.fk2023010116.
|
[18] |
Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms[J]. Endocr Pathol, 2022, 33(1):115-154. doi: 10.1007/s12022-022-09708-2.
pmid: 35294740
|
[19] |
Zheng HC, Xue H, Zhang CY. REG4 promotes the proliferation and anti-apoptosis of cancer[J]. Front Cell Dev Biol, 2022,10:1012193. doi: 10.3389/fcell.2022.1012193.
|